The epidermal growth factor receptor (EGFR) signaling pathway is an essential pathway that is involved in the proliferation of cancer cells, and monoclonal antibodies against EGFR like cetuximab (Erbitux®) and panitumumab (Vectibix®) have been used as a monotherapy in patients with wild‐type KRAS and NRAS tumors [257]. Here, KRAS is linked to cancer.